<DOC>
	<DOCNO>NCT00806481</DOCNO>
	<brief_summary>The purpose study determine whether lower phosphate patient early chronic kidney disease phosphate binder sevelamer beneficial effect cardiovascular structure function .</brief_summary>
	<brief_title>Effects Phosphate Binding With Sevelamer Stage 3 Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Chronic kidney disease patient age 18 80 year Chronic kidney disease stage 3 ( define glomerular filtration rate 3060 ml/min/1.73m2 ) Office blood pressure control less 140/90 mmHg 12 month entry study Total cholesterol le 5.5 mmol/l Existing previous treatment within 1 year phosphate binder vitamin D analogue Uncontrolled hyperphosphataemia ( serum phosphate &gt; 1.8 mmol/l ) Uncontrolled secondary hyperparathyroidism ( PTH &gt; 80 pg/ml ) Diabetes mellitus Pregnancy Moderatesevere cardiac valvular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Phosphate</keyword>
</DOC>